Company news
Kissei Pharmaceutical Co., Ltd. news in 2025
Kissei Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
October 7, 2025
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
August 6, 2025
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
July 30, 2025
The Opening of a new Office for Open Innovation in the Boston Area
April 1, 2025
Kissei Pharmaceutical Initiates Phase III Clinical Trial for GnRH Antagonist "Linzagolix" Indicated for Endometriosis
March 31, 2025
Kissei Pharmaceutical Initiates Additional Phase III Clinical Trial for Rovatirelin (KPS-0373) for the Treatment of Spinocerebellar Degeneration
March 14, 2025
Marketing Authorization for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE® in South Korea
January 20, 2025